ClinicalTrials.gg
Active, not recruitingNCT07285863Updated Oct 26, 2026

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

A Phase 4 interventional study of Secretin (human synthetic) - ChiRhoClin in Exocrine Pancreatic Insufficiency and Chronic Pancreatitis, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Other

How we know

Updated Oct 26, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Exocrine Pancreatic Insufficiency with a site in United States — 11 open to participants now, 13 under way, 1 of them phase 3. Exocrine Pancreatic Insufficiency · United States.

Planned enrollment
38th of 59
24 · median 31
Started
2026
with 5 others
Phase 4
13 of 73
2 open now
Primary completion
2027-03
later than 2 of 12 live
Registered
67th of 73
by date

Among the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, this one is the 38th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 4, reaches primary completion later than 2 of the 12 other live ones, and was the 67th registered.

Exocrine Pancreatic Insufficiency

136 studies on the registry are indexed under Exocrine Pancreatic Insufficiency; 26 are open to participants now.

Browse Exocrine Pancreatic Insufficiency studies →

Open to participants now

11 of the 73 studies in Exocrine Pancreatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Exocrine Pancreatic Insufficiency studies recruiting now, 12 (63%) set no upper age limit and 5 (26%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Exocrine Pancreatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.

03

Conditions studied

  • Exocrine Pancreatic Insufficiency
  • Chronic Pancreatitis

Keywords

  • pancreatic function test
  • Pancreatic fluid composition
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or non-pregnant females
  • Age 18-80.
  • Participants must be in good health based on medical history (ASA Class 3 or below)
  • Participants must be willing and able to provide
  • Receiving an endoscopic ultrasound for a non-pancreatic indication

Exclusion criteria

Exclusion Criteria

  • History of any form of pancreatitis and/or other pancreatic diseases (e.g. pancreatic cysts, pancreatic masses).
  • History of inflammatory bowel disease
  • History of vagotomy.
  • History of surgically altered upper gastrointestinal anatomy (e.g. gastric bypass, Billroth I/II)
  • History of liver disease
  • Pregnant women or nursing mothers
  • Regular use of anticholinergics
  • > 2 drinks of alcohol daily
  • Smokers (cigarette)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Healthy Participants

    Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.

    Drug: Secretin (human synthetic) - ChiRhoClin

Interventions

  • DrugSecretin (human synthetic) - ChiRhoClin

    During endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered

06

What researchers measure

Primary outcomes

  1. Pancreatic Fluid Bicarbonate Composition

    A primary outcome will be the bicarbonate level (milliequivalent per liter) in the pancreatic fluid collected.

    Time frame: 5, 10, 15, and 20-minutes post-secretin administration

  2. Pancreatic Fluid Sodium Composition

    A primary outcome will be the sodium level (milliequivalent per liter) in the pancreatic fluid collected.

    Time frame: 5, 10, 15, and 20-minutes post-secretin administration

  3. Pancreatic Fluid Potassium Composition

    A primary outcome will be the potassium level (milliequivalent per liter) in the pancreatic fluid collected.

    Time frame: 5, 10, 15, and 20-minutes post-secretin administration

  4. Pancreatic Fluid Chloride Composition

    A primary outcome will be the chloride level (milliequivalent per liter) in the pancreatic fluid collected.

    Time frame: 5, 10, 15, and 20-minutes post-secretin administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 16, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07285863
Lead sponsor
Mayo Clinic
Collaborators
ChiRhoClin, Inc.
Responsible party
Samuel Han (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Dec 16, 2025
Start date
Mar 11, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Samuel Han, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion